DayTwo, a Tel Aviv, Israel and San Francisco, CA-based microbiome human discovery platform that offers a glycemic control solution for people with type 2 diabetes, raised $31m in Series B financing.
The round, which brings total funding to $48M, was co-led by aMoon, together with Ofek Ventures, with participation from existing investors Seventure Partners and Johnson & Johnson. Previous funding rounds included contributions from the Mayo Clinic for the company’s validation trial, recently published in JAMA.
The company intends to use the funds to accelerate go-to-market initiatives in the United States and and to continue to develop a new generation of products and services for metabolic and gastrointestinal conditions.
Founded in 2015, and led by Lihi Segal, CEO, DayTwo provides a glycemic control solution that uses gut profiling and other clinical parameters to provide a food-as-medicine solution to enable glycemic control. Its personalized approach provides actionable insights into how the body metabolizes food and allows individuals to navigate what specific foods and meals to choose to balance their blood sugar levels.
The company’s food-as-medicine approach is based on the original research conducted by Professors Eran Segal, Ph.D., and Eran Elinav, M.D., Ph.D. at The Weizmann Institute of Science, published in the journal, Cell, in 2015.
DayTwo, which has 75 employees, completed the first quarter of 2019 with tens of thousands of individual customers, and hundreds of providers in the DayTwo clinician network. The company also launched a strategic partnership with Clalit, which now offers the DayTwo glycemic control solution to its 4.5 million members. It also continues to conduct ongoing research with clinical institutional partners including the Weizmann Institute of Science, the Israel Diabetes Association, Joslin Diabetes Center, Janssen a Pharmaceutical Company of Johnson & Johnson, and the Mayo Clinic.